多种不同PET或PET/CT分子探针在胶质瘤中的应用进展

Progress on application of different PET or PET/CT agents in glioma

  • 摘要: 胶质瘤是一种发病率最高的中枢神经系统原发性肿瘤, 约占颅内肿瘤的40%~50%, 其恶性程度及病死率极高, 加之病理学类型多样、生物学行为各异, 胶质瘤对各种治疗手段的反应也是不尽相同的。胶质瘤预后凶险, 尤其是高级别胶质瘤。CT是一种以组织密度差异来反映局部解剖结构的影像学检查方法, 它能清晰地显示组织结构, 但不能反映肿瘤的代谢状况。MRI虽然具有良好的组织分辨率, 也能从一定程度上反映肿瘤的代谢状况, 但依然具有一定的局限性。PET及PET/CT是一种相对而言比较新兴的检查方法, 主要反映肿瘤的代谢状况, 随着18F-FDG PET或PET/CT的广泛应用, 以及各种非FDG显像剂的发展, PET或PET/CT在胶质瘤诊断中的应用将越来越受到重视。

     

    Abstract: Glioma is the most common primary brain tumor, accounting for about 40%-50% of intracranial tumors. Patients have a poor prognosis and especially high-grade glioma. With various characteristics of histology and multiple biological behaviors, glioma has different responses to many types of treatment. CT and MRI are conventional imaging methods, while PET or PET/CT is relatively new. The latter mainly reflects tumor metabolism. CT reflects anatomy structure by utilizing the difference of tissue density. However, CT cannot estimate tumor metabolism. Although MRI has good tissue resolution and can also judge tumor metabolism, it still has some limitations. With the extensive use of 18F-FDG PET or PET/CT and the development of other imaging agents beyond FDG, the diagnostic value of PET or PET/CT in glioma is highly concerned.

     

/

返回文章
返回